GlassScriptPhysician profile
Aurelio D Manto
NPI 1982686846
$1,477.28
in general payments reported to CMS, 2019-2025
21 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.96 · 2022: $69.38 · 2024: $230 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.14 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $149.45 | 2024-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $142.11 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $137.68 | 2025 | Wainua |
| Pfizer INC. | $111.67 | 2024-2025 | |
| Edwards Lifesciences Corporation | $88.90 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bridgebio Pharma, INC. | $77.93 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $70.23 | 2025 | Opsumit, Opsynvi |
| Alnylam Pharmaceuticals INC. | $47.38 | 2025 | Amvuttra |
| Axsome Therapeutics, INC. | $44.81 | 2025 | Sunosi |
| Phathom Pharmaceuticals, INC. | $40.16 | 2024-2025 | Voquezna |
| Collegium Pharmaceutical, INC. | $32.50 | 2025 | Xtampza |
| Inspire Medical Systems, INC. | $31.85 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $24.75 | 2024 | Inpefa |
| Exact Sciences Corporation | $24.16 | 2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $23.84 | 2025 | Extended Holter |
| Averitas Pharma INC. | $23.38 | 2025 | Qutenza |
| Chiesi USA, INC. | $23.26 | 2025 | Juxtapid |
| Ionis Pharmaceuticals, INC. | $22.79 | 2025 | Tryngolza |
| Vertex Pharmaceuticals Incorporated | $21.20 | 2025 | |
| Lilly USA, LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurelio Manto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.